Clinical Trials Browser

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT06792695 2026-01-20

CANTOR

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06311851 2025-11-25

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Phase 1/2 Recruiting

40 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01187199 2025-10-27

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1 Active not recruiting

278 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT05678257 2025-09-12

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Phase 2 Terminated

180 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Phase 3 Not yet recruiting

740 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

NCT02885753 2025-07-09

OSCAR

Phase 3 Recruiting

348 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Phase 1 Terminated

272 enrolled

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

Clinical Trials

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

TRIPLET

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

CANTOR

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

OSCAR

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma